| Current molecular-targeted therapies in NSCLC and their mechanism of resistance Z Schrank, G Chhabra, L Lin, T Iderzorig, C Osude, N Khan, A Kuckovic, ... Cancers 10 (7), 224, 2018 | 125 | 2018 |
| Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC T Iderzorig, J Kellen, C Osude, S Singh, JA Woodman, C Garcia, N Puri Biochemical and biophysical research communications 496 (2), 770-777, 2018 | 44 | 2018 |
| Design and synthesis of megamolecule mimics of a therapeutic antibody JA Modica, T Iderzorig, M Mrksich Journal of the American Chemical Society 142 (32), 13657-13661, 2020 | 17 | 2020 |
| Mechanism of epithelial-mesenchymal transition in erlotinib resistance in NSCLC cells containing both wild-type and mutant EGFR S Singh, T Iderzorig, P Kumar, N Puri Cancer Research 78 (13_Supplement), 5456-5456, 2018 | | 2018 |
| Comparison of epithelial mesenchymal transition mediated TKI resistanc NSCLC cells containing wild type EGFR and mutant EGFR T Iderzorig, S Singh, G Chhabra, N Puri Cancer Research 77 (13_Supplement), 3336-3336, 2017 | | 2017 |
| PS01. 28: Epithelial Mesenchymal Transition in TKI Resistant NSCLC with T790M Mutation: Topic: Medical Oncology T Iderzorig, G Chhabra, N Puri Journal of Thoracic Oncology 11 (11), S286, 2016 | | 2016 |
| Epithelial mesenchymal transition and its role in TKI resistant NSCLC cell lines I Rastogi, T Iderzorig, G Chhabra, GM Botting, A Webb, B Foster, B Webb, ... Cancer Research 76 (14_Supplement), 1599-1599, 2016 | | 2016 |
